Caricamento...
New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1
Immunotherapy has significantly altered the treatment landscape for many cancers, including non-small cell lung cancer (NSCLC). Currently approved immuno-oncology agents for lung cancer are aimed at the reversal of immune checkpoints, programmed death protein-1 (PD-1) and programmed death ligand-1 (...
Salvato in:
| Pubblicato in: | Ther Adv Respir Dis |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6144513/ https://ncbi.nlm.nih.gov/pubmed/30215300 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1753466618794133 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|